X4 Pharmaceuticals, Inc. (XFOR)Healthcare | Biotechnology | Boston, United States | NasdaqCM
4.24 USD
+0.05
(1.193%)
⇧
(April 21, 2026, 10:51 a.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:29 a.m. EDT
X4 Pharmaceuticals presents a classic risk/reward split: a strong long-term thesis driven by revised FDA timelines, new mineral pair, leadership shake-up, and recent Guggenheim Buy initiation, but the short-term outlook is muted by negative volume-based prediction stats and ongoing revenue losses. The stock is well above its 50-day average and trades at a low premium to book value despite being pre-revenue, suggesting analysts see significant downside potential over the coming months despite the multi-year growth story. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.084690 |
| MSTL | 0.086636 |
| AutoETS | 0.087057 |
| AutoTheta | 0.087089 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 66% |
| H-stat | 1.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.526 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 41.486 |
| Revenue per Share | 0.83 |
| Market Cap | 385,499,488 |
| Forward P/E | -4.39 |
| Beta | 0.33 |
| Profit Margins | -225.56% |
| Website | https://www.x4pharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31198686 |
| Address1 | 61 North Beacon Street |
| Address2 | 4th Floor |
| All Time High | 5,164.92 |
| All Time Low | 1.35 |
| Ask | 5.33 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 415,630 |
| Average Daily Volume3 Month | 480,796 |
| Average Volume | 480,796 |
| Average Volume10Days | 415,630 |
| Beta | 0.326 |
| Bid | 3.06 |
| Bid Size | 2 |
| Book Value | 2.049 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.24 |
| Current Ratio | 10.156 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.255 |
| Day Low | 4.115 |
| Debt To Equity | 41.486 |
| Display Name | X4 Pharmaceuticals |
| Dividend Date | 1,552,521,600 |
| Earnings Call Timestamp End | 1,746,102,600 |
| Earnings Call Timestamp Start | 1,746,102,600 |
| Earnings Timestamp | 1,773,750,600 |
| Earnings Timestamp End | 1,777,638,600 |
| Earnings Timestamp Start | 1,777,638,600 |
| Ebitda | -78,606,000 |
| Ebitda Margins | -2.2386599 |
| Enterprise To Ebitda | -2.611 |
| Enterprise To Revenue | 5.845 |
| Enterprise Value | 205,240,528 |
| Eps Current Year | -0.87333 |
| Eps Forward | -0.965 |
| Eps Trailing Twelve Months | -1.87 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.8218 |
| Fifty Day Average Change | 0.41819978 |
| Fifty Day Average Change Percent | 0.10942482 |
| Fifty Two Week Change Percent | -31.198687 |
| Fifty Two Week High | 6.63 |
| Fifty Two Week High Change | -2.3900003 |
| Fifty Two Week High Change Percent | -0.3604827 |
| Fifty Two Week Low | 1.35 |
| Fifty Two Week Low Change | 2.8899999 |
| Fifty Two Week Low Change Percent | 2.1407406 |
| Fifty Two Week Range | 1.35 - 6.63 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,510,842,600,000 |
| Float Shares | 64,551,166 |
| Forward Eps | -0.965 |
| Forward P E | -4.393782 |
| Free Cashflow | -57,361,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.83603996 |
| Gross Profits | 29,356,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00629 |
| Held Percent Institutions | 0.90291 |
| Implied Shares Outstanding | 90,919,696 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,798,400 |
| Last Split Factor | 1:30 |
| Long Business Summary | X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts. |
| Long Name | X4 Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 385,499,488 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_283397098 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -79,199,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 381,862,723 |
| Number Of Analyst Opinions | 3 |
| Open | 4.23 |
| Operating Cashflow | -85,618,000 |
| Operating Margins | -9.30646 |
| Payout Ratio | 0.0 |
| Phone | 857 529 8300 |
| Previous Close | 4.19 |
| Price Eps Current Year | -4.85498 |
| Price Hint | 4 |
| Price To Book | 2.0693018 |
| Price To Sales Trailing12 Months | 10.978826 |
| Profit Margins | -2.25555 |
| Quick Ratio | 9.845 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.049999714 |
| Regular Market Change Percent | 1.1933106 |
| Regular Market Day High | 4.255 |
| Regular Market Day Low | 4.115 |
| Regular Market Day Range | 4.115 - 4.255 |
| Regular Market Open | 4.23 |
| Regular Market Previous Close | 4.19 |
| Regular Market Price | 4.24 |
| Regular Market Time | 1,776,783,081 |
| Regular Market Volume | 77,997 |
| Return On Assets | -0.22855 |
| Return On Equity | -0.75991994 |
| Revenue Growth | 0.791 |
| Revenue Per Share | 0.83 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 90,919,696 |
| Shares Percent Shares Out | 0.0344 |
| Shares Short | 3,123,686 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,456,380 |
| Short Name | X4 Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0344 |
| Short Ratio | 5.9 |
| Source Interval | 15 |
| State | MA |
| Symbol | XFOR |
| Target High Price | 13.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.66667 |
| Target Median Price | 12.0 |
| Total Cash | 252,998,000 |
| Total Cash Per Share | 2.783 |
| Total Debt | 77,285,000 |
| Total Revenue | 35,113,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.38045 |
| Two Hundred Day Average Change | 0.85954976 |
| Two Hundred Day Average Change Percent | 0.25427082 |
| Type Disp | Equity |
| Volume | 77,997 |
| Website | https://www.x4pharma.com |
| Zip | 2,134 |